TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11913309

Group type: EXPERIMENTAL
Intervention: AHDC chewing gum (5% sodium bicarbonate), 2 tablets for 20 minutes, 2 times daily
Number of subjects: 28

Group type: COMPARATOR
Intervention: Mint tablet (sugarless), 2 tablets for 20 minutes, 2 times daily
Number of subjects: 28
Study: 9477866

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 10
Study: 7701191

Group type: EXPERIMENTAL
Intervention: Modafinil (300 mg daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 3588258

Group type: EXPERIMENTAL
Intervention: Adjuvant oxygen therapy for 48 hours
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (no therapy)
Number of subjects: 39
Study: 29283132

Group type: EXPERIMENTAL
Intervention: Oral fenofibrate 160 mg/day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard treatment protocol (Control Group B)
Number of subjects: 50
Study: 28814275

Group type: EXPERIMENTAL
Intervention: Full dose monotherapy (S-1 30 mg/m2 twice daily days 1-14 every 3 weeks, followed by second line irinotecan 250-350 mg/m2 iv day 1 every 3 weeks or 180-250 mg/m2 iv day 1 every 2 weeks)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Reduced dose combination therapy (S-1 20 mg/m2 days 1-14 + oxaliplatin 100 mg/m2 iv day 1 every 3 weeks, followed by second line S-1 20 mg/m2 days 1-14 + irinotecan 180 mg/m2 day 1 every 3 weeks)
Number of subjects: 150
Study: 26316345

Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg BID
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1000
Study: 23292524

Group type: EXPERIMENTAL
Intervention: Atropine treatment for myopia
Number of subjects: 35

Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 30 Hz flicker response amplitude
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Longitudinal data
Number of subjects: 35
Study: 20921118

Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Adolescent-focused individual therapy (AFT)
Number of subjects: 121
Study: 19078912

Group type: EXPERIMENTAL
Intervention: Early walking and compression stockings (Group B)
Number of subjects: 219

Group type: COMPARATOR
Intervention: 5 days of bed rest (Group A)
Number of subjects: 219
Study: 16883916

Group type: EXPERIMENTAL
Intervention: Haoqin Qingdan Decoction (HQD) and prednisone
Number of subjects: 120

Group type: COMPARATOR
Intervention: Prednisone and cyclophosphamide (CTX)
Number of subjects: 120
Study: 12832308

Group type: EXPERIMENTAL
Intervention: Group visits
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study: 11122757

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 8867520

Group type: EXPERIMENTAL
Intervention: terguride (1 mg b.i.d.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: levodopa (250 mg p.o.)
Number of subjects: 20
Study: 1638712

Group type: EXPERIMENTAL
Intervention: Enalapril (2.5-20 mg/day)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 6396439

Group type: EXPERIMENTAL
Intervention: Home intermittent peritoneal dialysis (IPD)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Home hemodialysis (HD)
Number of subjects: 114
Study: 30362216

Group type: EXPERIMENTAL
Intervention: Percutaneous catheter drainage (PCD)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Percutaneous needle aspiration (PNA)
Number of subjects: 190
Study: 28960596

Group type: EXPERIMENTAL
Intervention: Psychosocial stress (depressive symptoms)
Number of subjects: 14577

Group type: EXPERIMENTAL
Intervention: Psychosocial stress (loss of interest)
Number of subjects: 14577

Group type: EXPERIMENTAL
Intervention: Psychosocial stress (financial stress)
Number of subjects: 14577

Group type: EXPERIMENTAL
Intervention: Living alone
Number of subjects: 14577

Group type: EXPERIMENTAL
Intervention: Being married vs being widowed
Number of subjects: 14577
Study: 27394149

Group type: EXPERIMENTAL
Intervention: Enteral Docosahexaenoic Acid (DHA)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sunflower Oil (SO)
Number of subjects: 34
Study: 24596360

Group type: COMPARATOR
Intervention: Control group from the BREX study (Group 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Follow-up patients not participating in any intervention study (Group 2)
Number of subjects: 0
Study: 22551252

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral group intervention
Number of subjects: 242

Group type: COMPARATOR
Intervention: Routine clinical practice (Control)
Number of subjects: 242
Study: 20636466

Group type: EXPERIMENTAL
Intervention: Educational intervention of four half-day workshops
Number of subjects: 163
Study: 18372701

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nutrition
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study: 15859528

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) treatment of the lower extremity
Number of subjects: 11
Study: 12602111

Group type: EXPERIMENTAL
Intervention: Pulsed magnetic field therapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 36
Study: 10749028

Group type: EXPERIMENTAL
Intervention: Vitamin E (n = 12 in each subgroup)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (n = 13 in each group)
Number of subjects: 50
Study: 7582337

Group type: EXPERIMENTAL
Intervention: Wet-to-dry saline gauze dressings changed twice a day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrocolloid dressing (HCD) DuoDERM changed when needed or once a week
Number of subjects: 0
Study: 1660009

Group type: EXPERIMENTAL
Intervention: Intravenous administration of 10,000 anti Xa units of LMWH
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Aortic administration before clamping of 10,000 anti Xa units of LMWH
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intra-aortic administration of 10,000 anti Xa units of LMWH
Number of subjects: 16

Group type: COMPARATOR
Intervention: Aortic injection after clamping of 10,000 anti Xa units of LMWH
Number of subjects: 16
Study: 7073642

Group type: EXPERIMENTAL
Intervention: Depressed mood induction
Number of subjects: 68

Group type: COMPARATOR
Intervention: Neutral mood induction
Number of subjects: 68

Group type: COMPARATOR
Intervention: Elated mood induction
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: High weight-fluctuation factor
Number of subjects: 68

Group type: COMPARATOR
Intervention: Concern for dieting factor
Number of subjects: 68
Study: 31567801

Group type: EXPERIMENTAL
Intervention: Short Decision Aid (short DA)
Number of subjects: 1220

Group type: COMPARATOR
Intervention: Long Decision Aid (long DA)
Number of subjects: 1220

Group type: EXPERIMENTAL
Intervention: Both DA groups (short DA and long DA)
Number of subjects: 1220

Group type: EXPERIMENTAL
Intervention: Surgeon group with patient preference report
Number of subjects: 1220

Group type: COMPARATOR
Intervention: Usual care surgeon group
Number of subjects: 1220
Study: 26940348

Group type: EXPERIMENTAL
Intervention: Usual services plus a 3-day manualized risk detection intervention
Number of subjects: 74

Group type: COMPARATOR
Intervention: Usual case management services
Number of subjects: 74
Study: 26778165

Group type: EXPERIMENTAL
Intervention: Early oral β blockers (administered ≤24 hours after hospital admission)
Number of subjects: 5259

Group type: COMPARATOR
Intervention: Delayed oral β blockers (administered >24 hours after hospital admission)
Number of subjects: 5259
Study: 25484042

Group type: EXPERIMENTAL
Intervention: ch‐mAb7F9, doses of 0.2 to 20 mg/kg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (implied control group)
Number of subjects: 42
Study: 22301525

Group type: EXPERIMENTAL
Intervention: NIDCAP (Newborn Individualized Developmental Care and Assessment Program)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 30
Study: 18839190

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided steroid injections
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Palpation-guided steroid injections
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Scintigraphy-guided steroid injections
Number of subjects: 27

Group type: COMPARATOR
Intervention: Comparison among ultrasound-guided, palpation-guided, and scintigraphy-guided injections
Number of subjects: 27
Study: 17166311

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation protocol
Number of subjects: 0
Study: 15164322

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/d)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (hypolipidic diet)
Number of subjects: 40
Study: 11494621

Group type: EXPERIMENTAL
Intervention: 5% carbamide peroxide
Number of subjects: 60

Group type: COMPARATOR
Intervention: 10% carbamide peroxide
Number of subjects: 60
Study: 9771053

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Number of subjects: 20
Study: 8276367

Group type: EXPERIMENTAL
Intervention: Vasopressin (0.4 U/min)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Glypressin (2-mg injection)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 2735328

Group type: EXPERIMENTAL
Intervention: sucralfate 2 g at night
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: cimetidine 400 mg
Number of subjects: 117

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 117
Study: 1172718

Group type: EXPERIMENTAL
Intervention: Warfarin sodium added to chemotherapy
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Streptokinase with surgery of tumors of the large bowel
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Brinase
Number of subjects: 128
Study: 31911640

Group type: EXPERIMENTAL
Intervention: Reduced FEV1
Number of subjects: 29266

Group type: EXPERIMENTAL
Intervention: Reduced FEV1/FVC
Number of subjects: 29266

Group type: EXPERIMENTAL
Intervention: Reduced FEV1/FVC in never smokers
Number of subjects: 29266
Study: 31220851

Group type: EXPERIMENTAL
Intervention: Targeted lung denervation (TLD) at 32 W
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Targeted lung denervation (TLD) at 29 W
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both doses of TLD (29 W and 32 W)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Open-label confirmation phase study
Number of subjects: 30
Study: 26055693

Group type: EXPERIMENTAL
Intervention: New reduced-dose Td vaccine
Number of subjects: 164

Group type: COMPARATOR
Intervention: Commercially available Td vaccine
Number of subjects: 164
Study: 26130075

Group type: EXPERIMENTAL
Intervention: Walking Away group - structured education programme with annual maintenance sessions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Walking Away Plus group - structured education programme with annual maintenance sessions, plus follow-on support through text-messaging and telephone calls
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group - detailed advice leaflet
Number of subjects: 0
Study: 23460567

Group type: EXPERIMENTAL
Intervention: Modified Brice interview (postoperative day 28-30)
Number of subjects: 18847

Group type: COMPARATOR
Intervention: Quality assurance data (postoperative day 1)
Number of subjects: 18847
Study: 21114896

Group type: EXPERIMENTAL
Intervention: Cognitive Control (CC) task
Number of subjects: 59

Group type: COMPARATOR
Intervention: Peripheral Vision (PV) comparison task
Number of subjects: 59
Study: 18289563

Group type: EXPERIMENTAL
Intervention: 120 mg intravenous papaverine hydrochloride
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: 75 mg intramuscular sodium diclofenac
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: papaverine hydrochloride plus sodium diclofenac
Number of subjects: 86
Study: 16048734

Group type: EXPERIMENTAL
Intervention: Zolpidem (ZOL) 10 mg orally
Number of subjects: 14

Group type: COMPARATOR
Intervention: Brotizolam (BTM) 0.25 mg orally
Number of subjects: 14
Study: 12480612

Group type: EXPERIMENTAL
Intervention: Tobramycin solution for inhalation, 300 mg, twice daily for 28 days
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 11190906

Group type: EXPERIMENTAL
Intervention: 325 mg of aspirin every third day
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: 81 mg of aspirin every day
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: 81 mg of aspirin every third day
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: 40 mg of aspirin every third day
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo every day
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo on other days
Number of subjects: 109
Study: 9287403

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 177
Study: 8422561

Group type: EXPERIMENTAL
Intervention: Chlormezanone 400 mg nocte
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 3018561

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 29466862

Group type: EXPERIMENTAL
Intervention: HIV-HBV coinfected patients with high HBV-DNA replication
Number of subjects: 808

Group type: COMPARATOR
Intervention: HIV-HBV coinfected patients with high HBV-DNA replication, HIV-HBV coinfected patients with low HBV-DNA replication, HIV monoinfection
Number of subjects: 808
Study: 28822879

Group type: EXPERIMENTAL
Intervention: CT + Memory Support Intervention
Number of subjects: 48

Group type: COMPARATOR
Intervention: CT-as-usual
Number of subjects: 48
Study: 25564105

Group type: EXPERIMENTAL
Intervention: Short-term medication-assisted treatment (ST-MAT) with buprenorphine/naloxone (BUP/NX) for 1 year, including 2 opportunities for a 15-day detoxification and up to 21 sessions of behavioral drug and risk counseling
Number of subjects: 1251

Group type: EXPERIMENTAL
Intervention: Long-term medication-assisted treatment (LT-MAT) with buprenorphine/naloxone (BUP/NX) for 48 weeks, including thrice-weekly dosing and up to 21 counseling sessions
Number of subjects: 1251

Group type: COMPARATOR
Intervention: Both ST-MAT and LT-MAT
Number of subjects: 1251
Study: 23529671

Group type: EXPERIMENTAL
Intervention: Hyperprolactinemic women
Number of subjects: 81

Group type: COMPARATOR
Intervention: Healthy premenopausal women
Number of subjects: 81
Study: 21112449

Group type: EXPERIMENTAL
Intervention: Behavioral treatment program focused on weight loss
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Behavioral treatment program focused on both weight loss and depression
Number of subjects: 203

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Change in depression and change in weight
Number of subjects: 203
Study: 18242455

Group type: EXPERIMENTAL
Intervention: Coaxial microincision cataract surgery (MICS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional coaxial cataract surgery
Number of subjects: 50
Study: 16612281

Group type: EXPERIMENTAL
Intervention: Tac
Number of subjects: 46

Group type: COMPARATOR
Intervention: CyA
Number of subjects: 46
Study: 15663227

Group type: EXPERIMENTAL
Intervention: Endoscopic carpal tunnel release (CTR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Open carpal tunnel release (CTR)
Number of subjects: 40
Study: 11041470

Group type: EXPERIMENTAL
Intervention: Urokinase (UK)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Heparinized saline (HS)
Number of subjects: 27
Study: 9310604

Group type: EXPERIMENTAL
Intervention: G‐CSF (filgrastim) therapy
Number of subjects: 40
Study: 8418721

Group type: EXPERIMENTAL
Intervention: 0.05 microgram/kg isoproterenol
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 0.075 microgram/kg isoproterenol
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 44
Study: 3543342

Group type: EXPERIMENTAL
Intervention: Butoconazole vaginal cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Miconazole nitrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30129320

Group type: EXPERIMENTAL
Intervention: Posterolateral approach (Yeung's technology) in group A (42 cases)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Transforaminal endoscopic spine system (TESSYS) technology in group B (40 cases)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Improved transforaminal endoscopic access (ITEA) technology in group C (43 cases)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Interlaminar approach in group D (40 cases)
Number of subjects: 165
Study: 27413037

Group type: EXPERIMENTAL
Intervention: Heart failure medication regimen (intense treatment)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Higher blood pressure and treatment with a β‐blocker or randomized to valsartan
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Ischemic pathogenesis, more dilated left ventricle, and detectable hs‐troponin
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Recovery of EF to >40%
Number of subjects: 321
Study: 24820121

Group type: EXPERIMENTAL
Intervention: Motivational enhancement physiotherapy
Number of subjects: 76
Study: 23036216

Group type: EXPERIMENTAL
Intervention: e‐TOKE program
Number of subjects: 245

Group type: COMPARATOR
Intervention: Assessment only (Control)
Number of subjects: 245
Study: 20670760

Group type: COMPARATOR
Intervention: Enrollment from lower-risk countries
Number of subjects: 2136

Group type: COMPARATOR
Intervention: Enrollment from higher-risk countries
Number of subjects: 2136

Group type: EXPERIMENTAL
Intervention: General clinical site diversity
Number of subjects: 2136
Study: 18662494

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 11515716

Group type: EXPERIMENTAL
Intervention: C-Med-100, 350 mg x 2 daily for two months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 0
Study: 9196675

Group type: EXPERIMENTAL
Intervention: Optical blur (defocus)
Number of subjects: 0
Study: 8199610

Group type: EXPERIMENTAL
Intervention: Binge days
Number of subjects: 47

Group type: COMPARATOR
Intervention: Nonbinge days
Number of subjects: 47
Study: 3540070

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 29614521

Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg twice daily or intravenous argatroban
Number of subjects: 94

Group type: COMPARATOR
Intervention: Subcutaneous enoxaparin 40 mg once daily
Number of subjects: 94
Study: 28624677

Group type: EXPERIMENTAL
Intervention: Weight management condition with group exercise classes
Number of subjects: 222

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 222
Study: 24709121

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Wait list
Number of subjects: 36
Study: 24427665

Group type: EXPERIMENTAL
Intervention: Clonidine (5 µg/Kg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 21372624

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Treatment (CBT)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Individualised Hypnosis
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Standardised Hypnosis
Number of subjects: 77

Group type: COMPARATOR
Intervention: General Anaesthesia (GA)
Number of subjects: 77
Study: 19032137

Group type: EXPERIMENTAL
Intervention: sorafenib
Number of subjects: 100

Group type: COMPARATOR
Intervention: best supportive care (BSC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: sorafenib vs. BSC
Number of subjects: 100
Study: 16798298

Group type: EXPERIMENTAL
Intervention: Group A (32F drain placed anteriorly and 16F thin drain placed retrocardially)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Group B (32F drain placed anteriorly only)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 140

Group type: COMPARATOR
Intervention: Group B
Number of subjects: 140
Study: 14966578

Group type: EXPERIMENTAL
Intervention: 0.1% cetylpyridinium chloride (CPC) rinse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Complex hibitane rinse (Control)
Number of subjects: 0
Study: 10634816

Group type: EXPERIMENTAL
Intervention: Folic acid (10 mg/d for 2 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9362716

Group type: EXPERIMENTAL
Intervention: Chinese version of the Nurse Stress Checklist (NSC)
Number of subjects: 138
Study: 1556522

Group type: EXPERIMENTAL
Intervention: Evening insulin therapy (Monotard HM or Ultratard HM), initial dose 10-16 U, mean dose 23 U d‐1 at 12 months
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Evening insulin therapy
Number of subjects: 17
Study: 30822629

Group type: EXPERIMENTAL
Intervention: 10-week educational program on CSA self-protection strategies (Group 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10-week educational program on CSA self-protection strategies (Group 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study: 29545530

Group type: EXPERIMENTAL
Intervention: Ketorolac as PCIA (NSAIDS group)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Morphine infusion as PCIA (morphine group)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both open RC and robot RC cases
Number of subjects: 70
Study: 26810403

Group type: EXPERIMENTAL
Intervention: Ingenol mebutate (IngMeb) 0.015% daily for 3 days followed by clobetasol propionate (0.05%) twice daily for 4 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ingenol mebutate (IngMeb) 0.015% daily for 3 days
Number of subjects: 0
Study: 25260632

Group type: EXPERIMENTAL
Intervention: Gly16+Glu27 haplotype
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Arg16+Gln27 haplotype
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Mental stress trial
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Handgrip and forearm vasodilation
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: ADRB2 density
Number of subjects: 71